True or False: A meta-analysis of 61 studies found that exercise showed anti-inflammatory trends, including reductions in CRP, IL-6, and TNF-α, in most chronic diseases. Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/7MxkveOuZE

JAMA Review: Postural Orthostatic Tachycardia Syndrome (POTS) POTS is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance. https://t.co/dAKlTp4VK3 https://t.co/A2UvgYOQN1

The Scleroderma Research Foundation (SRF) will konor John Stamos with the Bob Saget Legacy Award at this year's "Cool Comedy • Hot Cuisine" ceremony that will take place Tuesday, October 13, 2026, at the Beverly Wilshire in Los Angeles. Proceeds will support the SRF https://t.co/VHIpBJrXd4

Japanese study of 101 864 children shows fertility treatments (ovulation induction, intrauterine insemination, invitro fertilization) increases the risk of Kawasaki Dz. Incidence rates per 100K PYs - 274 for spont conception vs 391 for assisted conception (adj HR 1.42; https://t.co/Ro0beSXAAq

Guidelines for Adult-Onset IgA Vasculitis A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology, and pathology published evidence-based guidelines for adult-onset IgAV, which behaves very differently in adults than the usually https://t.co/mNuL4TG9Ua

Age-specific Incidence of Systemic Lupus Erythematosus Epidemiologic estimates on SLE diagnosis are limited. The CDC National Lupus Registry network of population-based SLE registries has assessed and reported age-specific incidence of SLE by sex, race, and ethnicity. https://t.co/g5A7DMQIyp

Phase 1/2 COMPARE trial of CD19 CAR-T Rx in 6 ACPA+ RA pts w/ severe refractory Dz; after lymphodepletion, given mivocabtagene autoleucel (miv-cel), followed < 52wks. All had CRS, No ICANSs or serious AEs. All had CD19 cell depletion & Decr in AutoAbs. Efficacy: 3/6 had ACR70 & https://t.co/qfSdq2g0rk

Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/lKBhEnTcKB

Does exercise affect inflammatory biomarkers? Metanalysis of 61 studies shows mostly low certainty evidence of inflammation-modulating effects of exercise. In most chronic diseases, exercise showed anti-inflammatory trends w/ reductions in CRP, IL-6, TNF-α https://t.co/EP74b3mVAT https://t.co/WBTHjsCzKL

Spyre Therapeutics topline results of its anti-TL1A Ab (SPY072) in RA (n 133) sub-study: Phase 2 SKYWAY 12wk trial showed 2 doses SPY072 were signif better vs PBO for ACR20 (63% & 58% vs 43%), ACR50 (31% &38% vs 19%), DAS28-CRP reductions (-1.5 & -1.9 vs -1.3). TL1A inhib are https://t.co/S6gapB21uq

Ivarmacitinib (AKA SHR-0302) is a JAK1 inhib approved in China. Phase II/III RCT (NCT04481139) in active #AS Rx w/ ivarmacitinib 4 mg (n 187) or placebo (n 186) showing IVRMA @wk 12 IVRMA had signif better ASAS20 response(49% vs 29%) & ASAS40 (32% vs 18%). Also superior: total https://t.co/ilVtrQgHxR

🔥 Still’s Disease Awareness Day 2026 🐉 I Won’t Be Still: Making Still’s Disease Visible Show us a moment from your life with Still’s Disease. 📸 Share a photo/video + what “I Won’t Be Still” means to you. For 47 hours, let’s make Still’s visible. #MyStills #StillsDay https://t.co/B7VNmlIOQj

CAR-T Reality Check! The hype is outrunning the evidence, which now lives in a handy dashboard created and presented by Dr. Mike Putman @EBRheum. There are almost as many studies as there are CAR-T treated patients. Few numbers, limited F/U - Yet everyone is gaga about CAR-T. https://t.co/aCtA8il2fD

🆕 #AutoInflammatory / Periodic Fever Syndromes In Memory of Dr. Dan Kastner🕊️ So grateful Dr. Kastner agreed to review this graphic >1 year ago, providing thoughtful input and suggestions to improve the final version 🙏 New Board Review Series for Rheum OnePagers 📟 #RheumX https://t.co/zx8dX2yHkA

Registry Data Shows Liver Risk With Avacopan A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from https://t.co/nHF6RVpq2Z